HLA Typing for Transplant Market

HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Kits, Software), Application (Antibody Screening), Type (Organ Transplant, Tissue), End User, and Region - Global Forecast to 2028

Report Code: BT 7584 Oct, 2023, by marketsandmarkets.com

The global HLA typing for transplant market in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.1 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the HLA typing for transplants market is mainly driven by factors such as the increasing number of transplantations worldwide, rising technological advancements in the field of HLA typing, and increasing public-private funding for target research activities. Moreover, government initiatives to promote organ donations increase the accessibility of transplant procedures, and commercialization high resolution HLA typing assay.

Attractive Opportunities in the HLA typing for transplants Market

HLA Typing for Transplants Market

To know about the assumptions considered for the study, Request for Free Sample Report

HLA Typing for Transplants Market

HLA Typing for Transplant Market Dynamics

Driver: Increasing number of transplant procedures globally

HLA matching provides numerous benefits in organ transplantation, including fewer rejection episodes, reduced immunosuppression, better graft function, and longer graft survival. The steady rise in the number of transplant procedures has increased the demand for timely and accurate HLA typing, thus bolstering the demand for instruments and kits.

  • According to the United Network for Organ Sharing (UNOS), in the US, organ transplant procedures increased from 39,701 in 2019 to 42,800 in 2022.
  • In the UK, kidney transplant procedures increased from 2,567 in 2020 to 3,192 in 2022 (Source: Global Observatory on Donation and Transplantation (GODT).
  • According to the Australian Donation and Transplantation Activity Report 2022, the number of kidney organ transplant recipients in Australia increased by 11% from 2021 (1,173) to 2022 (1,224).

This growth in procedural volumes and patient pool will ensure a sustained demand for donor-recipient HLA profiling and compatibility testing to eliminate the risk of immune rejection.

Restraint: High costs of molecular tests used for HLA typing procedures

HLA typing procedures for histocompatibility tests are conducted through specialized molecular diagnostic platforms that consist of several advanced technologies, such as NGS instruments to achieve the desired process outcomes, reduce cycle times, and increase sample throughput. However, innovative diagnostic instruments require significant capital investments and extensive scientific validation for market commercialization. For instance, NGS is a novel platform that integrates device automation and microfluidics for high sample throughput and effective genomic detection. The demand for premium-priced NGS-based assays is limited due to the preference for affordable or low-priced non-molecular assay techniques for HLA typing in transplant diagnostic testing owing to budget constraints.

OPPORTUNITY: Technological shift from non-molecular serological assays to gene-based HLA profiling

Traditionally, the donor-recipient screening process was carried out through the serology-based assay technique before a transplantation procedure. However, gene-based histocompatibility testing procedures have recently been increasingly preferred over serology-based assays. Molecular assay requires less analysis time, provides higher sample throughput, offers easy handling of multiple samples in one run, and requires a smaller amount of patient samples than serological assay techniques, thus increasing the adoption of molecular assay technologies for HLA profiling in transplant donor  patients.

CHALLENGE: Significant gap between organ availability and demand

There is a; considerable shortage of organs from donors in comparison to the high demand for organ transplants. The increasing number of  waiting list of organ tranplants has become a vhalalneging factor for HLA typing for transplant market.

HLA Typing For Transplant Market Ecosystem

Prominent companies in HLA typing for transplant market include Thermo Fisher Scientific (US), Illumina, Inc. (US), QIAGEN (Germany), CareDX (US),F. Hoffmann-La Roche Ltd. (Switzerland),Bio-Rad Laboratories, Inc. (US), Immucor, Inc. (US),  and Luminex Corporation (US)

HLA Typing for Transplants Market Ecosystem

In 2022, reagents & consumables to dominate the HLA typing for transplant industry, product & Service.

Based on the product & service, the HLA typing for transplant market is segmented into reagents & consumables, instruments, and software & services. In 2022, the reagents & consumables accounted for the largest share of the HLA typing for transplants  market. The higher utilization and repeated use of reagents & kits in HLA  typing by diagnostic laboratories & transplant centers growing demand for identification of accurate HLA alleles are likely to drive the the growth of the reagents & consumables segment.

In 2022, the molecular assay technologies segment accounted for the largest share of the HLA typing for transplant industry, by technology.

The HLA typing for transplant market, by technology, is segmented into molecular and non-molecular assay technologies. In 2022, the molecular assay technologies segment accounted for the largest share of the HLA typing for the transplants market. Molecular techniques, such as PCR and NGS allow for high-resolution HLA typing, and   faster turnaround to analyze and identify multiple alleles at HLA loci in comparison to traditional serology technology are likely to support the growth of the segment.

In 2022, The independent reference laboratories end-user segment accounted for the largest share of the HLA typing for transplant industry

Based on end-user, the HLA typing for transplant market is segmented into hospitals & transplant centers, independent reference laboratories, and research laboratories & academic institutes. In 2022, independent reference laboratories accounted for the largest share of the HLA typing for the transplants market. The large share of this segment can be attributed to the presence of advanced molecular technology offering high-resolution HLA typing, the growing number of reference laboratories offering HLA service, strong emphasis of reference of laboratories on investments in advanced HLA typing equipment in the field of HLA typing.

In 2022, North America to dominate in HLA typing for transplant industry

The HLA typing for transplant market is segmented into North America, Europe, Asia Pacific, Latin America and Middle-East Africa. North America is expected to dominate during the forecast period, primarily due surge in transplant procesures, well establish healthcare infrastructure,  high adoption of advanced diagnostic technologies, favoriable reimbursement policy, and strong presence of key manufactures offering high resolution HLA typing assays.

HLA Typing for Transplants Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The HLA typing for transplant market is dominated by players such as Thermo Fisher Scientific (US), Illumina, Inc. (US), QIAGEN (Germany), CareDX (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US)

Scope of the HLA Typing for Transplant Industry:

Report Metric

Details

Market Revenue in 2023

$0.8 billion

Estimated Value by 2028

$1.1 billion

Revenue Rate

Poised to grow at a CAGR of 6.3%

Market Driver

Increasing number of transplant procedures globally

Market Opportunity

Technological shift from non-molecular serological assays to gene-based HLA profiling

This research report categorizes the HLA typing for transplant market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Reagents & Consumables
  • Instruments
  • Software & Services

By Technology

  • Molecular Assay Technologies
    • PCR-Based Molecular Assays
      • Real-time PCR
      • Sequence-specific Primer-PCR
      • Sequence-specific Oligonucleotide-PCR
      • Other PCR-based Molecular Assays
    • Sequencing-based Molecular Assays
      • Sanger Sequencing
      • Next-generation Sequencing
      • Other Sequencing-based Molecular Assays
  • Non-molecular Assay Technologies

By Application

  • Diagnostic Applications
    • Antibody Screening
    • Chimerism Monitoring
    • Others
  • Research Applications

By Transplant Type

  • Solid Organ Transplant
  • Soft Tissue Transplant

By End User

  • Independent Reference Laboratories
  • Hospitals & Transplant Centers
  • Research Laboratories & Academic Institutes

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle-East Africa

Recent Developments of HLA Typing for Transplant Industry

  • In September 2023,  Omixon, Inc. (US) launched its NanoTYPE RUO Multiplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore’s MinION Platform.
  • In November 2022, Illumina, Inc. (US)  opened a new state-of-the-art Solutions Center in Dubai for expanding genomics research in Middle East
  • In March 2022, 021, Immucor, Inc. (US) launched MIA FORA NGS Express HLA Typing Software.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 29)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 REGIONS COVERED
           1.3.3 YEARS CONSIDERED
           1.3.4 CURRENCY CONSIDERED
    1.4 KEY STAKEHOLDERS 
    1.5 SUMMARY OF CHANGES 
    1.6 RECESSION IMPACT: HLA TYPING FOR TRANSPLANTS MARKET 
 
2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Key data from primary sources
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 GLOBAL HLA TYPING FOR TRANSPLANTS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION METHODOLOGY 
          FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
           2.2.2 PROCEDURE-BASED MARKET ESTIMATION
                    FIGURE 5 MARKET SIZE ESTIMATION: HLA TYPING FOR TRANSPLANTS MARKET
           2.2.3 PRIMARY RESEARCH VALIDATION
    2.3 DATA TRIANGULATION 
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 
           2.4.1 RESEARCH ASSUMPTIONS
           2.4.2 RESEARCH LIMITATIONS
    2.5 RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
 
3 EXECUTIVE SUMMARY (Page No. - 43)
    FIGURE 7 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE,  2023 VS. 2028
    FIGURE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2023 VS. 2028 (USD MILLION)
    FIGURE 9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2023 VS. 2028  (USD MILLION)
    FIGURE 10 HLA TYPING FOR TRANSPLANTS MARKET: GEOGRAPHIC SNAPSHOT (2022)
 
4 PREMIUM INSIGHTS (Page No. - 46)
    4.1 HLA TYPING FOR TRANSPLANTS MARKET OVERVIEW 
          FIGURE 11 INCREASING NUMBER OF TRANSPLANT PROCEDURES TO DRIVE MARKET
    4.2 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE & COUNTRY (2022) 
          FIGURE 12 REAGENTS & CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE  IN 2022
    4.3 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2023 VS. 2028 (USD MILLION) 
          FIGURE 13 MOLECULAR ASSAY TECHNOLOGIES SEGMENT TO RETAIN DOMINANCE  TILL 2028
    4.4 MOLECULAR ASSAY TECHNOLOGIES MARKET, 2023 VS. 2028 
          FIGURE 14 NGS TO REGISTER HIGHEST GROWTH
    4.5 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY END USER, 2023 VS. 2028 (USD MILLION) 
          FIGURE 15 INDEPENDENT REFERENCE LABORATORY SEGMENT TO DOMINATE MARKET TILL 2028
    4.6 HLA TYPING FOR TRANSPLANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028
 
5 MARKET OVERVIEW (Page No. - 50)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 HLA TYPING FOR TRANSPLANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing number of transplant procedures globally
                    5.2.1.2 Technological advancements in HLA typing
                    5.2.1.3 Government initiatives to boost HLA typing services in transplantation
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of molecular tests used for HLA typing
                                TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE  (AS OF 2022)
                    5.2.2.2 Limited reimbursements for target procedures in emerging countries
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising adoption of cross-matching and chimerism testing pre/post-transplantation
                    5.2.3.2 Technological shift from non-molecular serological assays to gene-based HLA profiling
           5.2.4 CHALLENGES
                    5.2.4.1 Significant gap in organ demand and supply
    5.3 PRICING ANALYSIS 
           5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
                    TABLE 3 INDICATIVE PRICING FOR HLA TYPING INSTRUMENTS, REAGENTS, AND KITS FOR TRANSPLANTATION
           5.3.2 AVERAGE SELLING PRICE OF HLA TYPING INSTRUMENTS, BY KEY PLAYER
                    TABLE 4 AVERAGE SELLING PRICE OF HLA TYPING FOR TRANSPLANT PRODUCTS
    5.4 PATENT ANALYSIS 
          FIGURE 18 PATENT ANALYSIS OF NEXT-GENERATION SEQUENCING TECHNOLOGIES
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 19 VALUE CHAIN ANALYSIS OF HLA TYPING FOR TRANSPLANTS MARKET: MAJOR VALUE-ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 20 HLA TYPING FOR TRANSPLANTS MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM MAPPING 
          FIGURE 21 HLA TYPING FOR TRANSPLANTS MARKET: ECOSYSTEM MAP
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 5 HLA TYPING FOR TRANSPLANTS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 DEGREE OF COMPETITION
    5.9 REIMBURSEMENT SCENARIO 
          TABLE 6 CPT CODES FOR MOLECULAR DIAGNOSTICS: HLA TESTING FOR TRANSPLANT HISTOCOMPATIBILITY
    5.10 REGULATORY LANDSCAPE 
          TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.10.1 NORTH AMERICA
                    5.10.1.1 US
                    5.10.1.2 Canada
           5.10.2 EUROPE
           5.10.3 ASIA PACIFIC
                    5.10.3.1 China
                    5.10.3.2 Japan
                                 TABLE 11 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.10.3.3 India
           5.10.4 LATIN AMERICA
                    5.10.4.1 Brazil
           5.10.5 MIDDLE EAST
    5.11 KEY CONFERENCES & EVENTS, 2023–2025 
           TABLE 12 HLA TYPING FOR TRANSPLANTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2023–2025
    5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 22 REVENUE SHIFT IN HLA TYPING FOR TRANSPLANTS MARKET
    5.13 TRADE ANALYSIS 
           5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                     TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY,  2018–2022 (USD MILLION)
                     TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY,  2018–2022 (USD MILLION)
    5.14 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MARKET PRODUCTS
                     TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MARKET PRODUCTS (%)
           5.14.2 BUYING CRITERIA
                     FIGURE 24 KEY BUYING CRITERIA FOR MARKET PRODUCTS
                     TABLE 16 KEY BUYING CRITERIA FOR HLA TYPING FOR MARKET PRODUCTS
 
6 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE (Page No. - 71)
    6.1 INTRODUCTION 
          TABLE 17 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
    6.2 REAGENTS & CONSUMABLES 
           6.2.1 REAGENTS & CONSUMABLES TO HOLD LARGEST MARKET SHARE
                    TABLE 18 HLA TYPING REAGENTS & CONSUMABLES MARKET, BY REGION,  2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 ADVANCEMENTS IN HLA-BASED GENOME PROFILING TO SUPPORT SEGMENT GROWTH
                    TABLE 19 HLA TYPING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.4 SOFTWARE & SERVICES 
           6.4.1 RISING DEMAND FOR INNOVATIVE SOFTWARE TO DRIVE MARKET
                    TABLE 20 HLA TYPING SOFTWARE & SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
 
7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY (Page No. - 76)
    7.1 INTRODUCTION 
          TABLE 21 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 MOLECULAR ASSAY TECHNOLOGIES 
          TABLE 22 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 23 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
           7.2.1 PCR-BASED MOLECULAR ASSAYS
                    TABLE 24 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 25 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    7.2.1.1 Sequence-specific primer-PCR
                               7.2.1.1.1 Growing public-private investments in research to support market growth
                                              TABLE 26 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
                    7.2.1.2 Sequence-specific oligonucleotide-PCR
                               7.2.1.2.1 Growing awareness of benefits among medical professionals to drive demand
                                              TABLE 27 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION,  2021–2028 (USD MILLION)
                    7.2.1.3 Real-time PCR
                               7.2.1.3.1 High cost of real-time PCR and procedural complexity to hamper market growth
                                             TABLE 28 REAL-TIME PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
                    7.2.1.4 Other PCR-based molecular assays
                                TABLE 29 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION,  2021–2028 (USD MILLION)
           7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
                    TABLE 30 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 31 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION,  2021–2028 (USD MILLION)
                    7.2.2.1 Sanger sequencing
                               7.2.2.1.1 Growing demand for high-throughput DNA sequencers to drive market
                                              TABLE 32 SANGER SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION)
                    7.2.2.2 NGS
                               7.2.2.2.1 High scalability, low turnaround time, and other advantages to boost adoption
                                              TABLE 33 NGS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    7.2.2.3 Other sequencing-based molecular assays
                                TABLE 34 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION,  2021–2028 (USD MILLION)
    7.3 NON-MOLECULAR ASSAY TECHNOLOGIES 
           7.3.1 REPLACEMENT OF NON-MOLECULAR TECHNIQUES WITH  DNA-BASED HLA TYPING TO HAMPER MARKET GROWTH
                    TABLE 35 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION,  2021–2028 (USD MILLION)
 
8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION (Page No. - 87)
    8.1 INTRODUCTION 
          TABLE 36 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 DIAGNOSTIC APPLICATIONS 
          TABLE 37 HLA TYPING FOR TRANSPLANTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 38 HLA TYPING FOR TRANSPLANTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
           8.2.1 ANTIBODY SCREENING
                    8.2.1.1 Rising number of recipients for transplant procedures to drive market growth
                                TABLE 39 ANTIBODY SCREENING MARKET, BY REGION, 2021–2028 (USD MILLION)
           8.2.2 CHIMERISM MONITORING
                    8.2.2.1 Rising trend of personalized transplant medicine for effective risk management to support market growth
                                TABLE 40 CHIMERISM MONITORING MARKET, BY REGION, 2021–2028 (USD MILLION)
           8.2.3 OTHER APPLICATIONS
                    TABLE 41 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
    8.3 RESEARCH APPLICATIONS 
           8.3.1 RISING INVESTMENTS AND SUPPORT FOR RESEARCH TO DRIVE MARKET
                    TABLE 42 HLA TYPING FOR TRANSPLANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
 
9 HLA TYPING FOR TRANSPLANTS MARKET, BY TRANSPLANT TYPE (Page No. - 93)
    9.1 INTRODUCTION 
          TABLE 43 HLA TYPING FOR TRANSPLANTS MARKET, BY TRANSPLANT TYPE,  2021–2028 (USD MILLION)
    9.2 SOLID ORGAN TRANSPLANTS 
           9.2.1 SOLID ORGAN TRANSPLANTS TO HOLD LARGEST MARKET SHARE
                    TABLE 44 HLA TYPING FOR SOLID ORGAN TRANSPLANTS MARKET, BY REGION,  2021–2028 (USD MILLION)
    9.3 SOFT TISSUE TRANSPLANTS 
           9.3.1 INCREASING BLOOD CANCER PREVALENCE TO BOOST DEMAND
                    TABLE 45 HLA TYPING FOR SOFT TISSUE TRANSPLANTS MARKET, BY REGION,  2021–2028 (USD MILLION)
 
10 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER (Page No. - 97)
     10.1 INTRODUCTION 
             TABLE 46 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.2 INDEPENDENT REFERENCE LABORATORIES 
             10.2.1 INDEPENDENT LABS TO HOLD LARGEST MARKET SHARE
                        TABLE 47 HLA TYPING FOR TRANSPLANTS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, 2021–2028 (USD MILLION)
     10.3 HOSPITALS & TRANSPLANT CENTERS 
             10.3.1 RISING TRANSPLANT VOLUMES TO DRIVE DEMAND FOR HLA TYPING
                        TABLE 48 HLA TYPING FOR TRANSPLANTS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, 2021–2028 (USD MILLION)
     10.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 
             10.4.1 RISING RESEARCH ACTIVITY TO DRIVE MARKET
                        TABLE 49 HLA TYPING FOR TRANSPLANTS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, 2021–2028 (USD MILLION)
 
11 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION (Page No. - 102)
     11.1 INTRODUCTION 
             TABLE 50 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             11.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 25 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
                        TABLE 51 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 52 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 53 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 54 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.2.2 US
                        11.2.2.1 US to hold largest market share
                                      FIGURE 26 US: SOLID ORGAN TRANSPLANTATIONS PERFORMED, 2019–2021
                                      TABLE 55 US: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 56 US: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 57 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 58 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Rising availability of transplant diagnostic products to support market growth
                                      TABLE 59 CANADA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 60 CANADA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 61 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 62 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
     11.3 EUROPE 
             11.3.1 EUROPE: RECESSION IMPACT
                        TABLE 63 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 64 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 65 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 66 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.3.2 GERMANY
                        11.3.2.1 Germany to dominate European HLA typing for transplants market
                                      TABLE 67 GERMANY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 68 GERMANY: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 69 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 70 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Rising number of transplant procedures to drive market
                                      TABLE 71 UK: NUMBER OF ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021
                                      TABLE 72 UK: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 73 UK: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 74 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 75 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.3.4 FRANCE
                        11.3.4.1 Growing adoption of MDx for donor-recipient compatibility testing to support market
                                      TABLE 76 FRANCE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 77 FRANCE: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 78 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 79 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Increasing solid organ transplantation procedures to drive market
                                      TABLE 80 SPAIN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 81 SPAIN: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 82 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 83 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.3.6 ITALY
                        11.3.6.1 Slowdown in Italian healthcare sector to limit market growth
                                      TABLE 84 ITALY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 85 ITALY: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 86 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 87 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 88 REST OF EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 89 REST OF EUROPE: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 90 REST OF EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 91 REST OF EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
     11.4 ASIA PACIFIC 
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
                        FIGURE 27 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
                        TABLE 92 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 93 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 94 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 95 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.4.2 CHINA
                        11.4.2.1 Healthcare infrastructural improvements to support market growth
                                      TABLE 96 CHINA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 97 CHINA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 98 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 99 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Increasing transplantation procedures to drive market
                                      TABLE 100 INDIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 101 INDIA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 102 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 103 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.4.4 JAPAN
                        11.4.4.1 Significant growth in chronic disease prevalence to support market growth
                                      TABLE 104 JAPAN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 105 JAPAN: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 106 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 107 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.4.5 AUSTRALIA
                        11.4.5.1 Rising number of solid organ transplantation procedures to support market growth
                                      TABLE 108 AUSTRALIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 109 AUSTRALIA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 110 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 111 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.4.6 SOUTH KOREA
                        11.4.6.1 Government support and medical coverage for transplantation to drive market
                                      TABLE 112 SOUTH KOREA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 113 SOUTH KOREA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 114 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 115 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.4.7 REST OF ASIA PACIFIC
                        TABLE 116 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 117 REST OF ASIA PACIFIC: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 118 REST OF ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 119 REST OF ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
     11.5 LATIN AMERICA 
             11.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 120 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 121 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 122 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 123 LATIN AMERICA HLA TYPING FOR TRANSPLANTS MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.5.2 BRAZIL
                        11.5.2.1 Brazil to dominate LATAM market
                                      TABLE 124 BRAZIL: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 125 BRAZIL: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 126 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 127 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.5.3 MEXICO
                        11.5.3.1 Rising medical tourism to drive market
                                      TABLE 128 MEXICO: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 129 MEXICO: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 130 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 131 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             11.5.4 REST OF LATIN AMERICA
                        TABLE 132 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 133 REST OF LATIN AMERICA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 134 REST OF LATIN AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 135 REST OF LATIN AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 GOVERNMENT INITIATIVES AND RISING GERIATRIC POPULATION TO SUPPORT ADOPTION
             11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 136 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 137 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 138 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER,  2021–2028 (USD MILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 147)
     12.1 OVERVIEW 
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             FIGURE 28 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HLA TYPING FOR TRANSPLANTS MARKET (2020 TO 2023)
     12.3 REVENUE SHARE ANALYSIS (2022) 
             FIGURE 29 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN HLA TYPING FOR TRANSPLANTS MARKET, 2019–2022 (USD MILLION)
     12.4 MARKET RANKING SHARE 
             FIGURE 30 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY KEY PLAYER, 2022
             TABLE 139 HLA TYPING FOR TRANSPLANTS MARKET: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 31 HLA TYPING FOR TRANSPLANTS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
     12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 32 HLA TYPING FOR TRANSPLANTS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (AS OF 2022)
     12.7 COMPETITIVE BENCHMARKING 
             FIGURE 33 COMPANY FOOTPRINT ANALYSIS: TOP FIVE PLAYERS
             TABLE 140 PRODUCT & SERVICE FOOTPRINT ANALYSIS (TOP FIVE PLAYERS)
             TABLE 141 REGIONAL FOOTPRINT ANALYSIS (TOP FIVE PLAYERS)
             TABLE 142 HLA TYPING FOR TRANSPLANTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
     12.8 COMPETITIVE SCENARIO 
             12.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
                        TABLE 143 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020–2023)
             12.8.2 DEALS
                        TABLE 144 KEY DEALS (2020–2023)
 
13 COMPANY PROFILES (Page No. - 159)
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
     13.1 KEY PLAYERS 
             13.1.1 THERMO FISHER SCIENTIFIC
                        TABLE 145 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
                        FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2022)
             13.1.2 ILLUMINA, INC.
                        TABLE 146 ILLUMINA, INC.: COMPANY OVERVIEW
                        FIGURE 35 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
             13.1.3 QIAGEN
                        TABLE 147 QIAGEN: COMPANY OVERVIEW
                        FIGURE 36 QIAGEN: COMPANY SNAPSHOT (2022)
             13.1.4 BIO-RAD LABORATORIES, INC.
                        TABLE 148 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
                        FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             13.1.5 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 149 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 38 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2022)
             13.1.6 CAREDX
                        TABLE 150 CAREDX: COMPANY OVERVIEW
                        FIGURE 39 CAREDX: COMPANY SNAPSHOT (2022)
             13.1.7 IMMUCOR, INC.
                        TABLE 151 IMMUCOR, INC.: COMPANY OVERVIEW
             13.1.8 LUMINEX CORPORATION (DIASORIN)
                        TABLE 152 DIASORIN S.P.A: COMPANY OVERVIEW
                        FIGURE 40 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
             13.1.9 TBG DIAGNOSTICS LIMITED
                        TABLE 153 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
                        FIGURE 41 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2022)
             13.1.10 FUJIREBIO
                        TABLE 154 FUJIREBIO: COMPANY OVERVIEW
             13.1.11 OMIXON, INC.
                        TABLE 155 OMIXON, INC.: COMPANY OVERVIEW
             13.1.12 GENDX
                        TABLE 156 GENDX.: COMPANY OVERVIEW
             13.1.13 BAG DIAGNOSTICS GMBH
                        TABLE 157 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW
             13.1.14 CREATIVE BIOLABS
                        TABLE 158 CREATIVE BIOLABS: COMPANY OVERVIEW
             13.1.15 PACBIO
                        TABLE 159 PACBIO: COMPANY OVERVIEW
                        FIGURE 42 PACBIO: COMPANY SNAPSHOT (2022)
     13.2 OTHER PLAYERS 
             13.2.1 HISTOGENETICS LLC
             13.2.2 SCISCO GENETICS, INC.
             13.2.3 INNO-TRAIN DIAGNOSTIK GMBH
             13.2.4 BIONOBIS
             13.2.5 QUEST DIAGNOSTICS
             13.2.6 SCIENCELL RESEARCH LABORATORIES, INC.
             13.2.7 BGI GENOMICS
             13.2.8 CEGAT GMBH
             13.2.9 PROIMMUNE LTD.
             13.2.10 CD GENOMICS
 
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 205)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the HLA typing for the transplants market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the HLA typing for transplants market. The primary sources from the demand side include medical OEMs,  CDMOs, and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

HLA Typing for Transplants Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2022, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the global HLA typing for transplants market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the HLA typing for transplants business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

To calculate the global market value, segmental revenues were calculated based on the revenue mapping of major solution/service providers. This process involved the following steps:

  • Generating a list of major global players/OEMs operating in the HLA typing for transplants market
  • Mapping the annual revenue generated by major global players from the HLA typing segment (or the nearest reported business unit/product category)
  • Revenue mapping of top players to cover at least ~75% of the global market share as of 2022
  • Extrapolation of the revenue mapping of major players to derive the global value of the market
  •  Extrapolating the global value of the HLA typing for transplants industry

HLA Typing for Transplants Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the global HLA typing for transplants market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the HLA typing for transplants market was validated using both top-down and bottom-up approaches.

Market Definition

HLA typing tests for transplant procedures are used to identify HLA antigens in accessing the transplant donor-recipient compatibility to avoid the risk of immune rejection in a recipient. These procedures are adopted for donor-recipient cross-matching, subject profiling, genotyping, and other related diagnostic purposes. Advancements in HLA typing technology allowing high resolution typing, and providing accurate analysis of HLA alleles reduce the risk of rejection or graft-versus-host disease, making transplantation a more viable option for patients.

Key Market Stakeholders

  • Manufacturers of HLA typing products for transplant 
  • Distributors of HLA typing products  for transplant 
  • Hospitals, Transplant Centers, reference laboratories, Cord Blood Banks
  • Research laboratories and  Academic Institutes
  • Organ Procurement Organizations (OPOs)
  • Non-government organizations
  • Government regulatory authorities
  • Contract manufacturers and third-party suppliers
  • Clinical research organizations (CROs)
  • Government and non-governmental regulatory authorities
  • Market research and consulting firms

Objectives of the Study

  • To define, describe, and forecast the HLA typing for transplants market on the basis of product & service, technology, application, transplant type , end user, and region
  • To provide detailed information regarding the major factors influencing the growth potential of the global HLA typing for transplants market (drivers, restraints, opportunities, challenges, and trends).
  • To analyze the micro markets with respect to individual growth trends, future prospects, and contributions to the global HLA typing for transplants market.
  • To analyze key growth opportunities in the global HLA typing for transplants market for key stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of market segments and/or subsegments with respect to four major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, Australia, South Korea, ASEAN region and the RoAPAC), and Rest of the world.
  • To profile the key players in the global HLA typing for transplants market and comprehensively analyze their market shares and core competencies.
  • To track and analyze the competitive developments undertaken in the global HLA typing for transplants market, such as product launches, agreements, expansions, and & acquisitions.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global HLA typing for transplants market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

Company Information

  • Detailed analysis and profiling of additional market players (up to 15)

Geographic Analysis

  • Further breakdown of the Rest of Europe's HLA typing for transplants market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among other
  • Further breakdown of the Rest of Asia Pacific HLA typing for transplants market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 7584
Published ON
Oct, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the HLA Typing for Transplant Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback